Advanced Enzyme Technologies Ltd

Advanced Enzyme Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Advanced Enzyme Technologies Ltd

₹ 370 -5.28%
12 May - close price
advancedenzymes.com BSE: 540025 NSE: ADVENZYMES
About

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]

Key Points

Market Position
The Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally. [1]

Website BSE NSE
  • Market Cap ₹ 4,142 Cr.
  • Current Price ₹ 370
  • High / Low ₹ 420 / 252
  • Stock P/E 30.7
  • Book Value ₹ 63.4
  • Dividend Yield 1.41 %
  • ROCE 24.1 %
  • ROE 20.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 40.4%

Cons

  • The company has delivered a poor sales growth of 9.82% over past five years.
  • Earnings include an other income of Rs.59.5 Cr.
  • Promoter holding has decreased over last 3 years: -6.61%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
83 85 97 91 92 86 77 101 87 125 116 96 116
59 61 70 67 63 65 64 79 73 94 86 72 90
Operating Profit 23 25 27 25 29 21 14 22 14 31 30 23 27
OPM % 28% 29% 28% 27% 32% 24% 17% 22% 16% 24% 26% 25% 23%
3 51 1 4 -16 54 2 1 5 54 3 -3 5
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax 23 73 25 25 10 72 12 21 16 81 30 18 29
Tax % 25% 8% 26% 25% 70% 7% 26% 26% 29% 9% 25% 26% 23%
18 67 18 19 3 67 9 15 11 74 22 13 22
EPS in Rs 1.56 6.04 1.64 1.71 0.28 6.00 0.82 1.36 0.99 6.61 1.99 1.18 1.99
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
125 139 173 212 222 247 283 273 312 365 351 453
91 103 124 162 169 170 183 200 236 260 280 342
Operating Profit 34 36 48 50 53 77 101 73 76 105 71 110
OPM % 27% 26% 28% 24% 24% 31% 36% 27% 24% 29% 20% 24%
1 1 6 5 6 9 7 9 9 40 61 60
Interest 5 4 3 3 3 1 0 0 0 0 1 0
Depreciation 8 7 8 8 9 9 9 10 10 11 11 12
Profit before tax 23 25 44 44 47 76 98 72 74 134 121 158
Tax % 14% 18% 21% 18% 25% 24% 28% 24% 25% 19% 15% 16%
20 21 35 36 35 58 71 55 56 108 102 132
EPS in Rs 1.81 1.92 3.10 3.22 3.16 5.19 6.36 4.88 4.97 9.67 9.15 11.78
Dividend Payout % 6% 10% 13% 16% 19% 12% 14% 21% 20% 53% 57% 11%
Compounded Sales Growth
10 Years: 13%
5 Years: 10%
3 Years: 13%
TTM: 29%
Compounded Profit Growth
10 Years: 21%
5 Years: 14%
3 Years: 34%
TTM: 32%
Stock Price CAGR
10 Years: %
5 Years: -4%
3 Years: 8%
1 Year: 25%
Return on Equity
10 Years: 16%
5 Years: 17%
3 Years: 20%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 22 22 22 22 22 22 22 22 22 22 22 22
Reserves 134 152 233 267 297 348 413 458 503 558 607 687
38 49 38 45 18 10 1 2 2 2 3 2
28 37 25 39 38 42 53 48 48 51 57 92
Total Liabilities 223 261 318 373 376 423 489 530 576 633 689 804
106 101 98 98 97 127 131 132 143 142 156 151
CWIP 5 7 8 10 7 10 7 9 11 22 21 49
Investments 27 53 103 120 120 121 184 189 201 256 290 345
84 99 108 145 151 165 166 200 220 213 221 259
Total Assets 223 261 318 373 376 423 489 530 576 633 689 804

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
33 22 21 23 35 46 84 37 50 52 63 89
-7 -27 -55 -22 -2 -25 -70 -14 -42 -3 -2 -34
-27 4 34 -1 -33 -19 -15 -11 -12 -57 -58 -58
Net Cash Flow -1 -0 -0 -0 0 2 -1 12 -4 -8 4 -4
Free Cash Flow 26 21 12 14 32 5 75 28 27 31 41 44
CFO/OP 114% 77% 64% 62% 90% 76% 110% 80% 88% 75% 120% 105%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 71 60 65 66 63 77 70 66 78 75 81 76
Inventory Days 389 393 300 234 249 245 240 295 228 268 260 230
Days Payable 74 75 50 90 66 56 85 75 54 60 58 101
Cash Conversion Cycle 386 378 316 210 246 265 226 286 252 283 283 205
Working Capital Days 61 65 108 58 93 126 109 141 131 155 151 190
ROCE % 14% 14% 18% 15% 15% 21% 24% 16% 15% 28% 20% 24%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Manufacturing Plants
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of R&D Centers
Number
R&D Spend as % of Sales
%
Fermentation Capacity
m3
Number of Enzymes & Probiotics
Number
Number of Proprietary Products
Number
Capacity Utilization
%
Number of Customers
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
46.52% 45.92% 43.62% 43.50% 43.02% 42.95% 42.92% 43.08% 43.08% 43.08% 43.04% 43.26%
21.89% 22.27% 22.54% 23.01% 12.03% 12.63% 12.57% 11.90% 23.45% 25.41% 25.85% 25.50%
7.58% 6.49% 6.98% 7.56% 8.08% 8.02% 8.17% 8.19% 8.45% 6.41% 5.51% 5.41%
24.02% 25.34% 26.88% 25.95% 36.87% 36.40% 36.31% 36.82% 25.00% 25.09% 25.62% 25.85%
No. of Shareholders 75,05272,64273,03468,64065,22266,75867,35165,32267,58969,63768,05166,193

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls